ACP
UNCY icon

Acuta Capital Partners’s Unicycive Therapeutics UNCY Stock Holding History

Acuta Capital Partners’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,959
Closed -$381K – 30
2026
Q1 		$381K Sell
57,959
-2,026
-3% -$13.3K 0.27% 27
2025
Q4 		$346K Hold
59,985
– – 0.24% 29
2025
Q3 		$262K Sell
59,985
-2,914
-5% -$12.7K 0.27% 27
2025
Q2 		$300K Sell
62,899
-172,390
-73% -$1.07M 0.42% 25
2025
Q1 		$1.35M Buy
235,289
+4,989
+2% +$30.4K 1.57% 21
2024
Q4 		$1.83M Buy
230,300
+32,380
+16% +$179K 1.84% 18
2024
Q3 		$807K Buy
+197,920
New +$795K 0.65% 27

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

Acuta Capital Partners's UNCY Position: Q2 2026 in Review

Acuta Capital Partners sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 57,959 shares — an estimated $381K sold.

Acuta Capital Partners first reported a position in UNCY in Q3 2024 and held it in 7 quarters. The position peaked at $1.83M in Q4 2024. 73 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Acuta Capital Partners reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 57,959 Unicycive Therapeutics shares in Q2 2026, an estimated $381K.
  • Acuta Capital Partners first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 7 quarters.
  • Acuta Capital Partners's Unicycive Therapeutics position peaked at $1.83M in Q4 2024.
  • 73 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.